




|                              |  | EMLc             | Codes ATC: J01CA04 |
|------------------------------|--|------------------|--------------------|
| Indication                   | Acute sinusitis  | Code ICD11: CA01 |                    |
| INN                          | Amoxicillin  |                  |                    |
| Type de médicament           | Chemical agent   |                  |                    |
| Groupes d'antibiotiques      | <b>A</b> ACCESS  |                  |                    |
| Type de liste                | Liste de base (EML)<br>(EMLc)  |                  |                    |
| Formulations                 | Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid (EMLc) ; 250 mg per 5 mL (as trihydrate) powder for oral liquid (EMLc)<br>Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection ; 500 mg in vial (as sodium) powder for injection ; 1 g in vial (as sodium) powder for injection<br>Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate) (EMLc) ; 500 mg (scored) (as trihydrate) (EMLc)<br>Oral > Solid > dosage form: 250 mg (as trihydrate) ; 500 mg (as trihydrate) |                  |                    |
| Historique des statuts LME   | Ajouté pour la première fois en 2017 (TRS 1006)<br>Modifié en 2021 (TRS 1035)<br>Modifié en 2023 (TRS 1049)  |                  |                    |
| Sexe                         | Tous   |                  |                    |
| Âge                          | Aussi recommandé pour les enfants  |                  |                    |
| Équivalence thérapeutique    | La recommandation concerne ce médicament spécifique  |                  |                    |
| Renseignements sur le brevet | Patents have expired in most jurisdictions<br>Lire la suite <a href="#">sur les brevets.</a>    |                  |                    |
| Wikipédia                    | <a href="#">Amoxicillin</a>   |                  |                    |
| DrugBank                     | <a href="#">Amoxicillin</a>   |                  |                    |

### Recommandation du comité d'experts

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of new formulations of amoxicillin (dispersible, scored tablet, 250 mg and 500 mg) to the EMLc. - the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc.

### Recommandations de la LME : Acute sinusitis

**Premier choix**

**Second choix**

amoxicillin

amoxicillin + clavulanic acid

